

**Prof. MUDr. David  
Cibula, Ph.D.**

**Přednosta**

**Klinika gynekologie, porodnictví a  
neonatologie 1. Lékařské fakulty  
Univerzity Karlovy a Všeobecné  
fakultní nemocnice v Praze**





**1. LÉKAŘSKÁ  
FAKULTA**  
Univerzita Karlova



**VŠEOBECNÁ FAKULTNÍ  
NEMOCNICE V PRAZE**

# **KARCINOM DĚLOŽNÍHO HRDLA A ENDOMETRIA**





## **Nové evropské doporučené postupy (výrazná česká stopa)**

Kalkulátor prognózy pro lékaře i pacientky

Nové možnosti biologické léčby v ČR

Výjimečné operační výkony ve VFN

Výsledky mezinárodní studie SENTIX pod vedením VFN



OPEN ACCESS

# ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023\*

David Cibula,<sup>1,2</sup> Maria Rosaria Raspollini,<sup>3</sup> François Planchamp ,<sup>4</sup> Carlos Centeno,<sup>5</sup> Cyrus Chargari ,<sup>6</sup> Ana Felix,<sup>7,8</sup> Daniela Fischerová ,<sup>1,2</sup> Daniela Jahnn-Kuch,<sup>9</sup> Florence Joly,<sup>10</sup> Christhardt Kohler,<sup>11,12</sup> Sigurd Lax,<sup>13,14</sup> Domenica Lorusso,<sup>15,16</sup> Umesh Mahantshetty,<sup>17</sup> Patrice Mathevet,<sup>18</sup> Raj Naik,<sup>19</sup> Remi A Nout,<sup>20,21</sup> Ana Oaknin ,<sup>22,23</sup> Fedro Peccatori,<sup>24</sup> Jan Persson,<sup>25,26</sup> Denis Querleu ,<sup>15,27</sup> Sandra Rubio Bernabé ,<sup>28</sup> Maximilian P Schmid,<sup>29</sup> Artem Stepanyan ,<sup>30</sup> Valentyn Svintsitskyi,<sup>31</sup> Karl Tamussino,<sup>32</sup> Ignacio Zapardiel ,<sup>33</sup> Jacob Lindegaard<sup>34</sup>

Radiotherapy and Oncology 184 (2023) 109682



ELSEVIER

Contents lists available at ScienceDirect

Radiotherapy and Oncology

journal homepage: www.thegreenjournal.com



Original Article

## ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023<sup>☆</sup>












David Cibula <sup>a,b,\*</sup>, Maria Rosaria Raspollini <sup>c</sup>, François Planchamp <sup>d</sup>, Carlos Centeno <sup>e</sup>, Cyrus Chargari <sup>f</sup>, Ana Felix <sup>g,h</sup>, Daniela Fischerová <sup>a,b</sup>, Daniela Jahnn-Kuch <sup>i</sup>, Florence Joly <sup>j</sup>, Christhardt Kohler <sup>k,l</sup>, Sigurd Lax <sup>m,n</sup>, Domenica Lorusso <sup>o,p</sup>, Umesh Mahantshetty <sup>q</sup>, Patrice Mathevet <sup>r</sup>, Mr Raj Naik <sup>s</sup>, Remi A Nout <sup>t,u</sup>, Ana Oaknin <sup>v,w</sup>, Fedro Peccatori <sup>x</sup>, Jan Persson <sup>y,z</sup>, Denis Querleu <sup>o,aa</sup>, Sandra Rubio Bernabé <sup>ab</sup>, Maximilian P. Schmid <sup>ac</sup>, Artem Stepanyan <sup>ad</sup>, Valentyn Svintsitskyi <sup>ae</sup>, Karl Tamussino <sup>af</sup>, Ignacio Zapardiel <sup>ag</sup>, Jacob Lindegaard <sup>ah</sup>

Virchows Archiv (2023) 482:935–966  
<https://doi.org/10.1007/s00428-023-03552-3>

ORIGINAL ARTICLE




## ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023\*

David Cibula<sup>1,2</sup>  · Maria Rosaria Raspollini<sup>3</sup> · François Planchamp<sup>4</sup>  · Carlos Centeno<sup>5</sup> · Cyrus Chargari<sup>6</sup>  · Ana Felix<sup>7,8</sup> · Daniela Fischerová<sup>1,2</sup>  · Daniela Jahnn-Kuch<sup>9</sup> · Florence Joly<sup>10</sup> · Christhardt Kohler<sup>11,12</sup> · Sigurd Lax<sup>13,14</sup> · Domenica Lorusso<sup>15,16</sup> · Umesh Mahantshetty<sup>17</sup> · Patrice Mathevet<sup>18</sup> · Raj Naik<sup>19</sup> · Remi A. Nout<sup>20,21</sup> · Ana Oaknin<sup>22,23</sup>  · Fedro Peccatori<sup>24</sup> · Jan Persson<sup>25,26</sup> · Denis Querleu<sup>15,27</sup>  · Sandra Rubio Bernabé<sup>28</sup>  · Maximilian P. Schmid<sup>29</sup> · Artem Stepanyan<sup>30</sup>  · Valentyn Svintsitskyi<sup>31</sup> · Karl Tamussino<sup>32</sup> · Ignacio Zapardiel<sup>33</sup>  · Jacob Lindegaard<sup>34</sup>

Received: 20 April 2023 / Revised: 20 April 2023 / Accepted: 24 April 2023 / Published online: 5 May 2023  
 © ESGO, ESTRO, ESP 2023

# Evropské mezinárodní doporučené postupy 2023





Nové evropské doporučené postupy

**Kalkulátor prognózy pro lékaře i pacientky**

Nové možnosti biologické léčby v ČR

Výjimečné operační výkony ve VFN

Výsledky mezinárodní studie SENTIX pod vedením VFN

Podpořeno grantem VFN (institucionální podpora vědy)



## CERVICAL CANCER – RECURRENCE RISK CALCULATOR

Model applicable for patients with early-stage cervical cancer (T1a–T2b) after primary surgical treatment.

Tumour histotype:

Squamous cell



Maximal tumour diameter:

20–39 mm



Grade:

Grade 2



Number of positive lymph nodes:

1



Lymphovascular space invasion:

Yes




CALCULATE

Model is developed on data from **4,343** patients treated in 20 tertiary centres on 4 continents.

It has been evaluated by 10-fold cross-validation within the imputed data set.

The resulting median **C index equals 0.732\***





# CERVICAL CANCER – RECURRENCE RISK CALCULATOR

Model applicable for patients with early-stage cervical cancer (T1a–T2b) after primary surgical treatment.

Tumour histotype: Squamous cell

Maximal tumour diameter: 20–39 mm

Grade: Grade 2

Number of positive lymph nodes: 1


Lymphovascular space invasion: Yes

**CALCULATE**

Model is developed on data from 4,343 patients treated in 20 tertiary centres on 4 continents.

It has been evaluated by 10-fold cross-validation within the imputed data set. The resulting median C index equals 0.732\*

## Annual Recurrence Risk Model



## Instructions for Physicians:

Enter the tumour characteristics and click on “calculate” to determine the annual recurrence risk and disease-free survival. The model can be used to plan an individual surveillance strategy based on prognostic factors.

## Instructions for Patients:

This model calculates the probability of cervical cancer recurrence in the five years post surgery, which depends on the characteristics of the primary disease.

How to read results: for example, a 3.4% annual recurrence risk at 2 years means that 3.4 out of 100 women will experience recurrence of the cancer 1-2 years post-surgery for primary disease.

### Disease-free survival (DFS) (Risk score = 41)


DFS represents a % probability of survival without disease recurrence at the respective time point.

Years since surgery	DFS (95% confidence interval)
1	93.0% (85.9%; 100.0%)
2	85.9% (75.3%; 96.4%)
3	80.1% (66.8%; 93.3%)
4	73.1% (56.4%; 89.9%)
5	73.1% (56.4%; 89.9%)

### Predicted type and localisation of recurrence


Type of recurrence	Isolated	76.9%
	Multifocal	23.1%
Recurrence localisation	Pelvic	53.8%
	Distant	30.8%
	Combined	15.4%

### DFS in the context of other risk groups



EJC, 2021 158:111-122.





Nové evropské doporučené postupy


Kalkulátor prognózy pro lékaře i pacientky

**Nové možnosti biologické léčby v ČR**

Výjimečné operační výkony ve VFN

Výsledky mezinárodní studie SENTIX pod vedením VFN

# IMUNOTERAPIE V ONKOLOGYNEKOLOGII



- **KARCINOM DĚLOŽNÍHO HRDLA**

**PEMBROLIZUMAB +/- BEVACIZUMAB, 1. dočasná úhrada VILP, hrazeno od 1. 7. 2023**

perzistentní, recidivující nebo metastazující karcinom děložního hrdla – 1. linie


- **KARCINOM ENDOMETRIA**

**PEMBROLIZUMAB + LENVATINIB, 1. dočasná úhrada VILP, hrazeno od 1. 5. 2023**


pokročilý nebo recidivující karcinom endometria u pacientek s progresí během/po předchozí terapii obsahující platinu

# Phase 3, randomized, double-blind, multicenter study of dostarlimab plus carboplatin-paclitaxel versus placebo plus carboplatin/paclitaxel in patients with primary advanced or recurrent EC. Primary Endpoint: PFS in dMMR/MSI-H Population

**HR 0.28**  
(95% CI, 0.162–0.495)  
**P<0.0001**



Dostarlimab + carboplatin/paclitaxel	53 (0)	48 (3)	44 (6)	39 (10)	34 (15)	31 (17)	30 (18)	29 (19)	28 (19)	27 (19)	25 (19)	19 (19)	13 (19)	9 (19)	9 (19)	4 (19)	1 (19)	0 (19)
Placebo + carboplatin/paclitaxel	65 (0)	57 (4)	54 (7)	34 (24)	26 (32)	14 (41)	12 (43)	12 (43)	11 (44)	8 (46)	8 (46)	7 (47)	4 (47)	3 (47)	3 (47)	2 (47)	1 (47)	0 (47)



Nové evropské doporučené postupy




Kalkulátor prognózy pro lékaře i pacientky

Nové možnosti biologické léčby v ČR

**Výjimečné operační výkony ve VFN**

Výsledky mezinárodní studie SENTIX pod vedením VFN


# OUT OF THE BOX



Cibula D: Pelvic exenteration for Gynecologic Cancer;  
 In: Principles of Gynecologic Oncology Surgery, Elsevier, 2019.


# QOLPEX study – přežití pacientek

- 74 patients (retrospective cohort)
  - 42 pelvic exenterations PE (14 anterior; 10 posterior; 18 total); Median FU 60 months
  - 32 extended pelvic exenterations (9 LEER; 7 OoB; 16 combination of PE with LEER/OoB); Median FU 40 months
- No significant difference in occurrence/ types of postoperative complications or adverse events



Median disease-specific survival: 49 months

Median overall survival: 45 months



Nové evropské doporučené postupy

Kalkulátor prognózy pro lékaře i pacientky


Nové možnosti biologické léčby v ČR

Výjimečné operační výkony ve VFN

**Výsledky mezinárodní studie SENTIX pod vedením VFN**


# SENTIX trial: 2016 - 2022

sentix@ceegog.eu

Trial Chair:	David Cibula		
Main Investigator:	Roman Kocian		
Central pathology review:	Pavel Dundr		
	Kristyna Nemejcova		
Trial coordinators:	Ivana Nohova, Irena Jasova		


		
		Principal Investigator
Asklepios Klinik Hamburg Altona	Germany	Christhardt Köhler
La Paz University Hospital	Spain	Ignacio Zapardiel
Hospital Clinico San Carlos Madrid	Spain	Pluvio J. Coronado Martín
MD Anderson Cancer Center	Spain	Francisco Javier de Santiago García
Hospital Clinic de Barcelona	Spain	Aureli Tomé
Hospital Universitari de Bellvitge	Spain	Jordi Ponce i Sebastià
Fundacion Instituto Valenciano de Oncologia	Spain	Cristina Zorrero
University Hospital of Canary Islands	Spain	Octavio Arencibia Sánchez
San Gerardo Hospital Monza	Italy	Fabio Landoni
Fondazione IRCCS Istituto Nazionale Tumori Milan	Italy	Francesco Raspagliesi
Academic Medical Center Amsterdam	Netherlands	Luc van Lonkhuijzen
Hospital Español de Buenos Aires	Argentina	Juan Carlos Staringer
Institute of Oncology Angel H. Roffo	Argentina	Marcela Ostojich
Trondheim University Hospital	Norway	Solveig Tingulstad
Instituto Portugues de Oncologia do Porto	Portugal	Almerinda Petiz
Kalafong Provincial Tertiary Hospital, University of Pretoria	South Africa	Leon C. Snyman
Medizinische Universität Graz	Austria	Karl Tamussino
Luzerner Kantonsspital	Switzerland	Barbara Kipp

		Principal Investigator
General University Hospital in Prague	Czech Republic	David Cibula
University Hospital Bulovka	Czech Republic	Borek Sehnal
University Hospital Ostrava	Czech Republic	Jaroslav Klát
University Hospital Plzeň	Czech Republic	Zdeněk Novotný
University Hospital Olomouc	Czech Republic	Radovan Pilka
Hospital České Budějovice	Czech Republic	Martin Michal
Tomas Bata Regional Hospital Zlín	Czech Republic	Pavel Havelka
University Hospital Brno	Czech Republic	Luboš Minář
University Clinical Centre Gdańsk	Poland	Dariusz Wydra
Swietokrzyskie Cancer Center Kielce	Poland	Kamil Zalewski, Marcin Misiek
Institute of Mother and Child Warsaw	Poland	Grzegorz Szewczyk
M.Sklodowska-Curie Memorial Institute, Krakow	Poland	Pawel Blecharz
University Hospital Trenčín	Slovakia	Peter Kaščák
University Hospital Bratislava	Slovakia	Mikuláš Redecha
Oncology Institute of East Slovakia Košice	Slovakia	Róbert Tóth
University Medical Centre Maribor	Slovenia	Maja Pakiž
University Medical Centre Ljubljana	Slovenia	Špela Smrkolj
University of Debrecen	Hungary	Róbert Póka
LISOD - Israeli Oncological Hospital Pityuty	Ukraine	Alla Vinnytska

		Principal Investigator
Cliniques Universitaires Saint-Luc	Belgium	Mathieu Luyckx
CHU Saint Pierre	Belgium	Dario Bucella
University Hospitals Leuven	Belgium	Toon Van Gorp
CHU de Liege, N.-D. des Bruyeres	Belgium	Frederic Kridelka
AZ Turnhout	Belgium	Isabelle Cadron



## EUS or MRI compared to final pathology (negative parametria and non-suspicious LN on preoperative staging)





Nové evropské doporučené postupy

Kalkulátor prognózy pro lékaře i pacientky

Nové možnosti biologické léčby v ČR

Výjimečné operační výkony ve VFN

Výsledky mezinárodní studie SENTIX pod vedením VFN